Operating profit before amortization: veracyte.com (VCYT)

Public company logo of Veracyte (VCYT)

High service margins and FCF growth at Veracyte, Inc. (VCYT) ensure stability, as evidenced by the operating profit history in cash terms, where 112.64 is recorded as the baseline value. The development of AI algorithms and the expansion of Afirma with Decipher stimulate growth. An impeccable reputation in molecular diagnostics and the trust of oncologists solidify its status as a scientific leader saving patients' lives.

VCYT Veracyte Diagnostics: Profit before payment of interest, taxes and amortization in the range 11/23/2025 - 11/10/2026

Summary analytical data breakdowns for Veracyte (VCYT)

- market price and analyst price targets:
Stock Price Veracyte Diagnostics|VCYT - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Veracyte|VCYT - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Veracyte|VCYT - Company Book Value|Market Value to Book Value Ratio veracyte.com|VCYT - Cumulative Company Assets
- business debt structure and liquidity details:
Debt to Capital Veracyte, Inc.|VCYT - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Veracyte Inc|VCYT - Company Aggregate Debts|Debts to Net Assets Veracyte|VCYT - Company Long-Term Debt|Short-Term Debt Volume Veracyte|Quick Liquidity veracyte.com
- business earnings and investment ratios data:
VCYT - Net Profit|Expected Net Profit Veracyte, Inc.|VCYT - Price to Earnings Ratio|Future Price to Earnings Multiple veracyte.com|VCYT - PEG Multiple|EV/EBITDA Multiple Veracyte|VCYT - Operating profit EBITDA|Net earnings per share for the last 12 months Veracyte|VCYT - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months veracyte.com|VCYT - Net earnings per share growth this year|Projected earnings per share increase next year Veracyte, Inc.
Summary company analytics:VCYT Veracyte Diagnostics
Manufactured product of Veracyte Corp

An investment audit of Veracyte, Inc. (VCYT) requires an analysis of daily cash returns from core operations, excluding non-recurring financial effects. This indicator captures the net daily cash flow from sales, allowing the company's total operating profit to track the scaling efficiency of its cloud database and the expansion of its diagnostic tests. A declining curve signals a slowdown in market monopolization, warning of the risk of purchasing an overvalued asset.

Competitors of Veracyte, Inc. (VCYT)

Operating profit EBITDA Caris Corp CAI|GH - Profit before payment of interest, taxes and amortization|CELC (celcuity.com) - Operating profit before amortization|GRAL: Operating profit EBITDA|Myriad Genetics Inc (MYGN) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Castle Biosciences Corp|Profit before payment of interest, taxes and amortization BNR|Operating profit before deduction of amortization VNRX (VolitionRx Limited)|BDSX - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Precipio PRPO|Operating income before deduction of amortization Check-Cap Ltd (CHEK)|Mainz Biomed - Operating profit EBITDA|Operating income before deduction of amortization OncoCyte Inc OCX